On January 5, 2018 Radius Health, Inc. (Nasdaq:RDUS), reported that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 11:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, California (Press release, Radius, JAN 5, 2018, View Source [SID1234522925]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors section of Radius’ website at View Source A replay of the webcast will be archived on Radius’ website for 30 days following the presentation.

On January 5, 2018 Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, reported that it is changing its name to Avid Bioservices, Inc. as part of its transition to a dedicated contract development and manufacturing organization (CDMO) (Press release, Peregrine Pharmaceuticals, MAY 5, 2018, View Source [SID1234522974]). In addition to the name change, the company is also adopting the new NASDAQ ticker symbol "CDMO" (NASDAQ:CDMO). The name and ticker symbol changes will both be effective as of market open on Monday, January 8, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As our organization transitions to a pure play CDMO, we believe it is appropriate to take advantage of the brand recognition that has been built within this highly specialized marketplace and to change the company’s name and conduct all future operations as Avid Bioservices," said Roger Lias, Ph.D., president and chief executive officer. "Over the past 15 years, Avid has established a reputation for CDMO excellence built on biologics manufacturing expertise and a track record of consistently meeting and exceeding the needs of its clients. This level of quality is highlighted by Avid’s receipt of multiple 2017 Contract Manufacturing Leadership Awards for Quality, Reliability, Capabilities, Expertise and Compatibility. We look forward to continuing to build the Avid brand as we work to grow and diversify our CDMO business by providing our clients with the most sophisticated and highest-quality development and manufacturing services."

Effective at market open on Monday, January 8, 2018, trading for Avid Bioservices will begin under the symbol "CDMO" (NASDAQ:CDMO). At the same time, the company’s preferred stock will begin trading under the symbol "CDMOP" (NASDAQ:CDMOP). The company’s common stock and preferred stock will continue to trade under the ticker symbols "PPHM" and "PPHMP", respectively, until market close on Friday, January 5, 2018. The corporate name change to Avid Bioservices does not affect the rights of the company’s stockholders and no action is required by stockholders with respect to the name change. The company’s common stock has been assigned a new CUSIP number of 05368M 106 and the company’s preferred stock has been assigned a new CUSIP number of 05368M 205 in connection with the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.

On January 5, 2018 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that it will release its financial results for the 2017 fourth quarter and full year before the market opens on Wednesday, January 31, 2018, and will hold a conference call on the same day at 8:30 a.m. EDT (Press release, Thermo Fisher Scientific, JAN 5, 2018, View Source [SID1234522926]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the call, the company will discuss its fourth quarter financial performance, as well as future expectations. To listen, call (844) 579-6824 within the U.S. or (763) 488-9145 outside the U.S. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can be found in that section of our website under "Financial Results." A replay of the call will be available under "Webcasts and Presentations" through Thursday, February 1, 2018.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

On January 5, 2018 Affimed N.V. presented January 2018 Corporate Presentation (Presentation, Affimed, JAN 5, 2018, View Source [SID1234522927]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 5, 2018 Potenza Therapeutics reported insights into its portfolio of immuno-oncology therapies that turn on or off the signaling mechanisms that control a patients‘ own immune system to recognize and destroy cancer (Press release, Potenza Therapeutics, JAN 5, 2018, View Source [SID1234523024]). The lead program in Potenza’s portfolio is its next-generation checkpoint inhibitor, a novel TIGIT antagonist PTZ-201 (ASP8374) which is being developed in partnership with Astellas Pharma Inc. and its affiliates ("Astellas"). In addition, Potenza and Astellas are jointly working on two additional preclinical molecules expected to complete IND-enabling studies in 2018: PTZ-329, which targets a novel immune regulatory pathway; and PTZ-522, a novel approach to a well-validated but as-yet ineffectively addressed immune activating pathway.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The team has made substantial scientific discovery and pre-clinical development progress since we launched Potenza in 2014 and established our R&D Collaboration with Astellas in April 2015," said Dan Hicklin, PhD, co-founder of Potenza and the company’s Chief Executive Officer. "The current portfolio was carefully chosen and includes potential therapies that will be studied for use alone, in combination with standard of care, and in unique combination regimens with each other. The three programs that Potenza is pursuing may have the potential to provide benefit for patients in indications for whom there are currently no effective treatments."

The Phase 1 clinical trial for PTZ-201 (ASP8374) is a dose escalation and expansion safety study in patients with advanced solid tumors with plans to expand into efficacy expansion cohorts in responding tumor types, and is sponsored by Astellas Pharma Global Development, Inc. The primary purpose of the study is to evaluate the tolerability and safety profile of ASP8374 in patients with locally advanced (unresectable) or metastatic solid tumors and to characterize the pharmacokinetic profile of ASP8374 and to determine the recommended Phase 2 dose (RP2D) of ASP8374. The secondary purpose of this study is to evaluate whether ASP8374 has an anti-tumor effect as monotherapy and ultimately in combination with a PD1 inhibitor. Details can be found at www.clinicaltrials.gov.